CLINICAL LEARNING GUIDE

ANAMORELIN

Anamorelin Hydrochloride (ONO-7643) | Oral GHS-R1a Agonist

Mechanisms, Evidence, and Clinical Applications in Cancer Cachexia

Based on lecture and slide materials by William Seeds, MD — SSRP Institute | Cellular Medicine Education

For educational and research purposes only. Not medical advice. Anamorelin is approved in Japan for cancer cachexia only; not approved by FDA or EMA. Consult qualified healthcare providers.

SECTION 1 · PROFILE OF THE COMPOUND

Overview

Anamorelin hydrochloride (brand name: ADLUMIZ; investigational code: ONO-7643) is a first-in-class orally active, non-peptidic ghrelin receptor agonist. It is the only approved pharmacological treatment for cancer cachexia in the world — approved in Japan in January 2021 for cachexia in patients with non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, and colorectal cancer.

Unlike the GHRH analogs reviewed in this course (e.g., sermorelin, Mod GRF 1-29, tesamorelin), anamorelin is not a peptide and does not act on the GHRH receptor. It is a small molecule that selectively targets the growth hormone secretagogue receptor type 1a (GHS-R1a) — the same receptor activated by ghrelin (the stomach-derived 'hunger hormone') and by GHRP-class peptides such as ipamorelin and GHRP-2. Its clinical novelty lies in combining meaningful anabolic (lean body mass) effects with direct central appetite stimulation in a once-daily oral format, without the injection burden of peptide-based therapies.

Generic Name	Anamorelin hydrochloride
Trade Name	ADLUMIZ (Japan); investigational code ONO-7643
Molecular Formula	$C_{31}H_{42}N_6O_3 \cdot HCl$ (MW 546.7 g/mol as free base; 583.2 g/mol as HCl salt)
Compound Class	Non-peptidic, orally active GHS-R1a (ghrelin receptor) agonist; small molecule
Route of Administration	Oral — once daily tablet; taken before meals on an empty stomach
Standard Dose	100 mg once daily orally
Half-Life	6–7 hours
Tmax (time to peak)	0.5–1.75 hours (rapid oral absorption; biphasic peak pattern)
Cmax (males, 100 mg)	~745 ng/mL; females show ~1.8–1.9× higher AUC — no clinical dosing adjustment required
FDA Status	NOT approved; Phase 3 completed; NDA not submitted as of 2025
EMA Status	NOT approved; CHMP negative opinion December 2017 (rationale: handgrip strength endpoint not met)
Japan Approval	Approved January 2021 — NSCLC, gastric, pancreatic, colorectal cancer cachexia
Approved Indications	Cancer cachexia characterized by anorexia and weight loss (Japan only; all other uses investigational)

What Sets Anamorelin Apart in This Class

Anamorelin occupies a unique clinical position for several reasons:

- It is the only molecule in the GHRH/GHRP class series that is taken orally — no injection is required
- It is the only globally approved pharmacological treatment specifically for cancer cachexia
- Unlike megestrol acetate or corticosteroids (existing appetite stimulants), it increases lean body mass rather than fat mass
- It acts on two critical pathways simultaneously: central appetite stimulation (hypothalamic GHS-R1a) and peripheral anabolic signaling (pituitary GH → hepatic IGF-1)
- It is a small molecule GHS-R1a agonist — pharmacologically analogous to MK-677 (ibutamoren) but with a distinct molecular structure and an established oncology-specific evidence base

Regulatory Context: Why the FDA and EMA Did Not Approve It

The ROMANA 1 and ROMANA 2 Phase 3 trials (N=979 combined) demonstrated statistically significant increases in lean body mass and body weight, and significant symptom improvement. However, the co-primary endpoint of handgrip strength improvement was not met in either trial (p=0.15 and p=0.65 respectively). The EMA's CHMP issued a negative opinion based on this functional endpoint failure, despite acknowledging the LBM data as positive. The FDA did not receive a New Drug Application. Japan's PMDA approved the drug on the basis of the LBM and appetite data alone — a regulatory decision that reflects a different weighting of what constitutes meaningful benefit in cancer cachexia.

The functional endpoint gap is a scientific question, not a safety concern. The most evidence-supported explanation is that lean mass accumulation requires concurrent resistance exercise to translate into measurable strength — particularly in a population with active cancer-related inflammatory mediators (TNF-α, IL-6) that directly impair actin-myosin contractility. Trials did not include structured exercise programs.

SECTION 2 · MODES OF ACTION AND MECHANISMS

Primary Target: GHS-R1a (Ghrelin Receptor)

Anamorelin selectively binds and activates the growth hormone secretagogue receptor type 1a (GHS-R1a), a G protein-coupled receptor expressed in two critical locations:

- Hypothalamus (arcuate nucleus): central appetite regulation
- Anterior pituitary somatotrophs: GH secretion
- Peripheral tissues: skeletal muscle, liver, immune cells

GHS-R1a is the endogenous receptor for ghrelin — a 28-amino acid acylated peptide produced primarily in the stomach, which signals hunger, promotes energy storage, and stimulates GH release. Anamorelin mimics the N-terminal active core of ghrelin with substantially enhanced oral bioavailability. Native ghrelin requires intravenous administration; anamorelin achieves bioavailability sufficient for once-daily oral dosing. GHS-R1a has constitutive (ligand-independent) activity — it signals basally even without ghrelin bound, and anamorelin potentiates this activity further.

Intracellular Signaling Cascade

1. Anamorelin binds GHS-R1a → Gq/11 protein coupling
2. Gq/11 activates Phospholipase C (PLC) → IP3 + DAG generation
3. IP3 triggers intracellular calcium (Ca^{2+}) mobilization from the endoplasmic reticulum
4. DAG activates Protein Kinase C (PKC) → downstream phosphorylation cascades
5. ↑ intracellular Ca^{2+} → GH vesicle exocytosis from pituitary somatotrophs
6. PI3K/Akt pathway activation → promotes cell survival and metabolic regulation
7. AMPK activation in hypothalamic arcuate nucleus neurons → drives hunger signaling

This signaling architecture is identical to that activated by GHRP-class peptides (ipamorelin, GHRP-2, GHRP-6) at the GHS-R1a receptor, and is distinct from the Gs/cAMP/PKA pathway used by GHRH analogs (sermorelin, Mod GRF 1-29, tesamorelin) at the GHRHR. Anamorelin activates the IP3/Ca^{2+} arm exclusively — not the cAMP arm.

The Two-Site Mechanism: Pituitary + Hypothalamus

Anterior Pituitary (GHS-R1a on somatotrophs)	GH secretion is stimulated in a dose-dependent manner. GH acts on hepatic GH receptors → IGF-1 synthesis. IGF-1 and IGFBP-3 increase within days of initiation (observed in pigs and humans). Anabolic effects: IGF-1 promotes skeletal muscle protein synthesis via PI3K/Akt/mTOR and suppresses protein degradation via FOXO pathway inhibition. GH tachyphylaxis develops with repeated dosing — GH response attenuates over time — but IGF-1 remains elevated, preserving the downstream anabolic signal.
Hypothalamic Arcuate Nucleus (GHS-R1a on appetite neurons)	Stimulates NPY/AgRP neurons (orexigenic — pro-appetite), while inhibiting POMC/CART neurons (anorexigenic). AMPK activation drives hunger signaling. Result: dose-dependent increase in food intake, improved appetite perception, and reversal of cancer-related anorexia. This is distinct from the pituitary effects and occurs independently through hypothalamic GHS-R1a populations. Appetite improvement is often detectable within days.

Anti-Inflammatory Mechanism: Breaking the Cachexia Cycle

Cancer cachexia is driven primarily by elevated pro-inflammatory cytokines — particularly TNF-α and IL-6 — released by the tumor and the host immune response. These cytokines:

- Suppress appetite through central inflammatory signaling
- Drive muscle proteolysis (ubiquitin-proteasome and autophagy-lysosomal pathways)
- Impair actin-myosin contractility even in retained muscle mass — explaining why strength may not improve even when LBM increases
- Accelerate the inflammation-anorexia-wasting cycle

GHS-R1a activation by anamorelin modulates the NF-κB signaling pathway — a master transcription factor controlling pro-inflammatory cytokine production. This reduces TNF-α and IL-6 output, potentially attenuating muscle proteolysis and the inflammatory drive of cachexia. This anti-inflammatory effect complements the anabolic GH/IGF-1 actions — making anamorelin mechanistically suited to address multiple pathological nodes of cachexia simultaneously rather than a single symptom.

GH Tachyphylaxis vs. Sustained IGF-1 — A Key Pharmacological Point

With repeated daily dosing, the GH response at the pituitary attenuates — this is GH tachyphylaxis, also observed with GHRP-class peptides. However, IGF-1 levels remain elevated throughout treatment. This dissociation is clinically important: the anabolic downstream signal (IGF-1) is maintained even as the upstream pulse (GH) diminishes. The GH axis self-limits and cannot be hyperstimulated — a built-in safety property shared with all GHS-R1a agonists that preserve hypothalamic-pituitary feedback architecture.

Tumor Safety: The Critical Signal from Clinical Trials

A foundational concern with any GH-axis-activating agent in cancer patients is whether IGF-1 elevation could accelerate tumor growth. The available data from anamorelin trials provides meaningful — though not definitive — reassurance:

- In all Phase 2 and Phase 3 trials (including ROMANA 1, ROMANA 2, ROMANA 3, and the Japanese GI cancer studies), tumor progression was not accelerated in anamorelin-treated patients relative to placebo

- IGF-1 increases observed were within normal physiological ranges, not supraphysiologic
- IGFBP-3 (IGF-1's principal binding protein) rose in parallel with IGF-1, maintaining the free-to-bound ratio within expected physiological bounds
- No drug-related deaths were reported across trials; the safety profile was consistently comparable to or better than placebo in cancer patient populations

Additionally, Dr. Schally's later work with GHRH analogs demonstrated inhibitory effects on certain cancers — supporting the broader concept that physiological GH axis stimulation does not necessarily promote tumor growth. These observations require larger, longer studies with cancer-specific endpoints before definitive conclusions can be drawn. Active malignancy with suspected GH-sensitive tumor biology remains a point requiring individualized clinical judgment.

SECTION 3 · POINTS OF CLINICAL RELEVANCE

- **1.** Anamorelin is the only globally approved pharmacological agent for cancer cachexia — and it works by a mechanism no other approved drug uses.

Megestrol acetate increases fat mass and carries significant risks (thromboembolism, adrenal suppression). Corticosteroids provide transient appetite stimulation while worsening muscle wasting long-term. No currently approved drug increases lean body mass in cancer cachexia. Anamorelin does. The ROMANA 1 and ROMANA 2 trials (combined N=979) demonstrated statistically significant LBM gains of +0.65 to +0.99 kg over 12 weeks versus placebo losses of −0.47 to −0.98 kg — a meaningful separation in actively cachectic oncology patients.

- **2.** The failure to improve handgrip strength is not a drug failure — it is an exercise gap.

The inflammatory mediators driving cancer cachexia — particularly TNF-α and IL-6 — directly impair skeletal muscle contractility at the cellular level (actin-myosin interaction). Building lean mass in the presence of active cancer-related inflammation does not automatically translate to functional strength. Resistance exercise is the bridge. Trials did not include structured exercise programs. Anamorelin creates the anabolic substrate — exercise converts that substrate into function. This is not a minor footnote; it is the central clinical challenge that separates anamorelin from the full therapeutic outcome patients need.

- **3.** The neutrophil-to-lymphocyte ratio (NLR) is a clinically actionable biomarker for patient selection and response prediction.

Real-world and trial data consistently show that baseline NLR <4.4 predicts better treatment response and improved 1-year overall survival with anamorelin. NLR reflects the balance between innate immune activity (neutrophils, which can promote the tumor inflammatory environment) and adaptive immune function (lymphocytes, which include anti-tumor effectors). A high NLR signals a more inflammatory tumor environment — one where cachexia is more severe and less responsive to anabolic intervention. Checking NLR at baseline and at 4 weeks is low-cost, immediately available from a standard CBC, and clinically actionable.

- **4.** Earlier intervention is unambiguously better — pre-cachexia is the optimal treatment window.

Refractory cachexia — characterized by ECOG PS ≥3, life expectancy <3 months, and treatment-resistant wasting — shows minimal benefit from anamorelin. The drug works best when the patient retains sufficient physiological reserve to respond to anabolic stimulation and appetite improvement. Pre-cachexia (<5% weight loss but with anorexia and metabolic changes) and early cachexia (≥5% weight loss, still responding to treatment) are the optimal windows. Waiting for refractory cachexia before initiating is the most common clinical error.

- **5.** Multimodal management is not optional; it is mechanistically required.

Anamorelin addresses anorexia and lean mass. It does not address tumor biology, protein deficiency, physical deconditioning, or the psychosocial dimensions of cachexia. Evidence-based multimodal management combines anamorelin with: (1) high-protein nutrition (1.2–1.5 g/kg/day); (2) supervised resistance exercise; (3) anti-inflammatory support (omega-3 fatty acids — may enhance resolution of inflammation); (4) nutritional counseling; (5) effective anti-tumor therapy as the primary intervention. The drug is a supportive agent, not a stand-alone treatment.

- **6.** Oral dosing is a practical clinical advantage in the oncology setting.

Cancer patients often have significant injection fatigue from chemotherapy, port access, and supportive medications. Anamorelin's once-daily oral format removes injection burden entirely — a meaningful quality-of-life consideration for adherence in this population. The pharmacokinetics support once-daily dosing (t½ 6–7 hours, Tmax 0.5–1.75 hours, rapid absorption), and no dose adjustment is required for age or gender despite the ~1.8–1.9× higher AUC observed in female patients.

- **7.** The potential beyond cancer cachexia is an important emerging frontier.

Anamorelin's mechanism — GHS-R1a agonism driving appetite, LBM accretion, and anti-inflammatory signaling — is not conceptually limited to cancer. Sarcopenia of aging, COPD-related cachexia, cardiac cachexia, and post-surgical catabolism represent potential investigational domains. No regulatory-grade evidence exists for non-cancer indications, but active research is underway and the mechanistic rationale is sound.

SECTION 4 · GENERAL DOSING INSTRUCTIONS AND DELIVERY OPTIONS

Approved and Investigated Dosing

Standard approved dose	100 mg once daily orally (Japan approval; used in ROMANA 1/2/3 Phase 3 trials)
Phase 2 dose range	50 mg and 100 mg once daily studied; 100 mg showed superior LBM (+1.56 kg by DXA in Japanese Phase 2 trial at 100 mg vs +0.99 kg at 50 mg)
Dose adjustment	None required for age (≥65 vs. younger: no significant PK difference) or gender (despite higher AUC in females, no clinical significance identified in trials)
Timing	Before meals — on an empty stomach. At least 90–120 minutes of fasting before dose preferred; wait 30 minutes after dose before eating. Appetite stimulation begins rapidly post-dose.
Meal recommendation	Taking before breakfast or dinner (if ≥2 hours post-last meal) are the most practical timing options. The post-dose appetite surge can be leveraged to support a high-protein meal.
Treatment duration	12–24 weeks based on clinical trial evidence; Japan label supports ongoing use if benefit is maintained. Consider discontinuation if no response (≥5% body weight gain + appetite improvement) after 8–12 weeks.
Administration with chemotherapy	No significant drug interactions reported in trials. Anamorelin has been administered concurrently with chemotherapy in all major trials without clinically relevant pharmacokinetic interactions.

Defining Treatment Response: Cachexia Clinical Response (CCR)

The response criterion used in Japanese clinical practice and trials:

- ≥5% body weight gain from baseline, AND
- Improved appetite score (assessed via FAACT-A/CS or similar validated tool)

In the Naito 2022 low-BMI cohort, 43.2% met CCR body weight criteria at 9 weeks; 61.0% met appetite criteria. Real-world GI cancer data showed a 63.6% overall response rate. If no CCR response is observed by weeks 8–12, reassess the clinical situation, check NLR, and consider discontinuation.

The Dosing Context: Why the Empty Stomach Matters

Like GHRP-class peptides, GHS-R1a agonists are blunted by the insulin response that follows carbohydrate or fat ingestion. Elevated insulin suppresses GH release. For optimal GH and appetite effects from anamorelin:

- Take on an empty stomach — avoid high-carbohydrate or high-fat meals in the 90–120 minutes before dosing
- Wait 30 minutes post-dose before the first meal — this allows the appetite stimulation effect to manifest and the GH response to occur without insulin interference
- The post-dose meal should be protein-rich — leverage the appetite stimulation to achieve the target 1.2–1.5 g/kg/day protein intake

Staging-Based Initiation Guidance

Pre-Cachexia (<5% weight loss, anorexia present)	BEST window for initiation — maximum physiological reserve. Start anamorelin 100 mg daily immediately alongside nutritional optimization and exercise. Monitor NLR as a risk stratification tool.
Cachexia (≥5% weight loss or BMI <20)	Standard indication. Initiate 100 mg daily. Multimodal approach is essential. Assess CCR at 8–12 weeks. Address nutritional deficits concurrently.
Refractory Cachexia (ECOG PS ≥3, life expectancy <3 months)	Limited expected benefit. Focus shifts to palliative symptom management and comfort. Anamorelin is unlikely to produce meaningful CCR in this stage — balance potential benefit against pill burden in end-of-life care.

SECTION 5 · EVIDENCE PROFILE

Clinical Trial Evidence

Category	Study / Evidence	Key Finding
Phase 3 RCT	ROMANA 1 — Temel et al., Lancet Oncol 2016 (N=484, NSCLC + cachexia, 12 weeks, anamorelin 100 mg vs placebo)	LBM: +0.99 vs −0.47 kg (P<0.0001). Body weight: +2.20 vs +0.14 kg (P<0.001). Anorexia/cachexia symptoms: +4.12 vs +1.92 (P<0.001). Handgrip strength: not significant (P=0.15). Well tolerated; hyperglycemia Grade 3–4 <1%.
Phase 3 RCT	ROMANA 2 — Temel et al., Lancet Oncol 2016 (N=495, NSCLC + cachexia, 12 weeks)	LBM: +0.65 vs −0.98 kg (P<0.0001). Body weight: +0.95 vs −0.57 kg (P<0.001). Anorexia/cachexia symptoms improved (P=0.002). Handgrip strength: not significant (P=0.65). Consistent with ROMANA 1 findings.
Phase 3 Extension	ROMANA 3 — Currow et al., Ann Oncol 2017 (24-week safety extension of ROMANA 1/2)	Durable efficacy maintained through 24 weeks. AE incidence: 52.2% vs 55.7% (anamorelin vs placebo). No drug-related deaths. Grade ≥3 AEs comparable between groups (22.4% vs 21.6%). Safety confirmed for extended use.
Phase 2 RCT	Garcia et al., Lancet Oncol 2015 (N=82, integrated Phase 2 analysis, mixed advanced cancer, 50 mg vs placebo, 12 weeks)	Significant increase in total and appendicular LBM vs placebo. GH, IGF-1, and IGFBP-3 significantly increased and within normal range. Improved patient-reported symptoms. Well tolerated.
Phase 2 RCT	Katakami et al., Cancer 2018 — ONO-7643-04 (N=181 Japanese NSCLC patients, 50 mg vs 100 mg vs placebo, 12 weeks)	100 mg: LBM +1.56 kg by DXA (significant). Significant body weight and appetite improvement at both doses. Handgrip strength improvement not

		statistically significant. Safe; AEs lower in anamorelin groups than placebo.
Clinical Trial	Hamauchi et al., Cancer 2019 — ONO-7643-05 (GI cancer: colorectal, gastric, pancreatic, with cachexia)	LBM improvement +1.89 ± 0.36 kg in combined GI cohort. Improved anorexia symptoms. Consistent with NSCLC data. Supported Japan's approval extension to GI cancer types.
Clinical Trial	Naito et al., Cancer 2022 (Low BMI cohort: BMI <20, cancer cachexia, 9–24 weeks)	43.2% met CCR body weight criteria at 9 weeks; 61.0% met appetite criteria. Durable efficacy through 24 weeks. Real-world GI cancer data: 63.6% response rate. Age ≥75 attenuated response.
Clinical Trial	Leese et al., Clin Pharmacol Drug Dev 2015 (PK/PD and safety by age and gender, anamorelin 50–100 mg)	No significant PK differences between ≥65 and younger subjects. Females showed ~1.8–1.9× higher AUC — no clinical dosing adjustment required. Rapid absorption (Tmax 0.5–1.75 h). GH and IGF-1 dose-dependently elevated. Well tolerated.
Clinical Trial (Post-hoc)	Takayama et al., Cancer Med 2023 (Subgroup analyses of ROMANA 1/2 data)	ADR frequency: 19.2% in <65 yr vs ~60% in ≥75 yr — significant age-related increase in adverse events. Higher ADR rates in ECOG PS 2 (60%) vs PS 0–1 (38.4%). NLR ≥5 associated with reduced response.
Animal Study	Pietra et al., J Cachexia Sarcopenia Muscle 2014 (Preclinical profile in rodent and pig models)	Dose-dependent GH secretion (AUC 0–6h increased at 10 and 30 mg/kg in rats). IGF-1 production confirmed in pigs and humans within days. Appetite stimulation dose-dependent in rats. Anti-inflammatory cytokine reduction demonstrated (TNF-α, IL-6).
Review	Fujii et al., Anticancer Res 2025 (Comprehensive review: clinical efficacy, challenges, future directions)	Synthesizes ROMANA 1/2/3 and Japanese data. Recommends multimodal approach. Identifies exercise as the missing component for functional improvement. Discusses NLR-guided patient selection and future non-cancer cachexia indications.
Review	Zhang & Garcia, Expert Opin Pharmacother 2015; Prommer, Palliat Care 2017	Comparative analysis vs. megestrol acetate and corticosteroids. Anti-inflammatory mechanism (NF-κB, TNF-α, IL-6) synthesis. Palliative care clinical context for anamorelin use.

Cachexia Therapy Comparative Analysis

Feature	Anamorelin	Megestrol Acetate	Corticosteroids
Mechanism	GHS-R1a (ghrelin receptor) agonist — appetite + anabolic (GH/IGF-1) + anti-inflammatory	Progestational agent — appetite stimulant via unknown mechanism	Anti-inflammatory — corticosteroid receptor; short-term appetite effect
LBM Effect	Increases lean body mass (Phase 3 RCT confirmed)	Primarily increases fat mass — no LBM benefit	Temporary; may worsen muscle loss with prolonged use
Evidence Base	Phase 3 RCTs (ROMANA 1/2/3, N=979); multiple Phase 2 trials; real-world data	Multiple RCTs; FDA-approved for AIDS cachexia	Short-term appetite studies only; no LBM benefit demonstrated

Key AEs	Hyperglycemia <5%; hepatic enzyme elevation (reversible); mild GI effects	Thromboembolic events; adrenal suppression; risk of HPA axis suppression	Immunosuppression; myopathy; hyperglycemia; adrenal insufficiency
Regulatory	Approved Japan (cancer cachexia); investigational elsewhere	FDA-approved (AIDS cachexia); off-label cancer use	Not approved for cachexia; short-term palliative use only

Evidence Classification Summary

- Phase 3 RCT: Strong — for LBM increase, body weight gain, and anorexia/cachexia symptom improvement in NSCLC (ROMANA 1/2, N=979)
- Phase 3 RCT: Strong — for safety and tolerability (ROMANA 3, 24-week extension, no drug-related deaths)
- Phase 2 RCT: Moderate-Strong — for LBM and appetite benefit in NSCLC and mixed solid tumors (Garcia 2015, Katakami 2018)
- Clinical Trial: Moderate — for GI cancer types (Hamauchi 2019, Naito 2022, Wakabayashi 2021)
- Clinical Trial: Moderate — for PK/PD safety across age and gender (Leese 2015)
- Mechanistic/Animal: Moderate — for anti-inflammatory mechanism (TNF-α, IL-6 reduction, NF-κB modulation)
- Consistent finding across all trials: Handgrip strength improvement NOT demonstrated — functional gap persists without exercise

Critical Evidence Gaps

- Handgrip strength / functional outcomes: The most clinically urgent unresolved question. No trial has combined anamorelin with structured resistance exercise to test whether the LBM-function gap closes with adequate physical activity.
- Overall survival benefit: No survival benefit was detected in the ROMANA trials. Whether LBM maintenance confers survival advantage in larger or longer trials is unknown. The mass-survival link in cachexia is biologically plausible but not yet demonstrated for anamorelin specifically.
- Non-cancer cachexia: No regulatory-grade evidence for sarcopenia, COPD, cardiac cachexia, or aging-related muscle loss. Mechanistic rationale exists; dedicated trials are needed.
- Optimal treatment duration: Trials used 12–24 week courses. Whether continuous therapy is superior to cycled therapy, and what the optimal duration for different cachexia stages is, remains undefined.
- GH-sensitive tumor safety: While no tumor acceleration was observed in trials, the theoretical concern about IGF-1 in GH-sensitive tumor histologies (e.g., certain sarcomas, IGF-pathway-driven tumors) has not been formally addressed with tumor-specific safety endpoints.
- Age ≥75 optimization: Significantly attenuated response and higher ADR rates in elderly patients — no dedicated trial has evaluated dose adjustment or modified protocols for this population.
- Combination with exercise — the key open trial: This is the most clinically important gap. A well-designed RCT of anamorelin + resistance exercise vs. anamorelin alone vs. exercise alone in cancer cachexia could resolve the mass-function gap and the EMA's primary objection.

SECTION 6 · CLINICAL CONSIDERATIONS

Contraindications

- Known hypersensitivity to anamorelin or any excipient in the formulation
- Uncontrolled diabetes mellitus — hyperglycemia risk (<5% incidence but real; requires glucose stability before initiating)
- Severe hepatic impairment — AST/ALT elevations observed at doses ≥50 mg; reversible on discontinuation; monitor hepatic function closely

- Refractory cachexia with ECOG PS ≥3 and life expectancy <3 months — limited expected benefit; assess appropriateness in palliative context
- Pregnancy and lactation — insufficient safety data; avoid
- Not approved for non-cancer cachexia — use outside approved indications is investigational; ensure informed consent is documented

Precautions

- Age ≥75: ADR frequency increases substantially (approximately 19% in <65 years vs. ~60% in ≥75 years). Initiate with close monitoring; consider whether benefit-risk ratio is favorable in elderly patients with multiple comorbidities.
- Pre-existing diabetes or pre-diabetes: Monitor blood glucose closely; anamorelin's GH-stimulating effects can transiently blunt insulin sensitivity.
- ECOG PS 2: Higher ADR rates (60%) compared to PS 0–1 (38.4%). More frequent assessment warranted.
- High baseline NLR (≥5): Attenuated response expected; reassess appropriateness or consider whether other cachexia management strategies should be prioritized.
- GH-sensitive tumor histologies: Theoretical concern — individualize based on tumor type, treating oncologist input, and available evidence. No acceleration of tumor progression was observed in trials, but this remains a monitoring priority.
- Concurrent medications: No clinically significant drug interactions identified in trials. Anamorelin was administered safely alongside standard chemotherapy regimens.

Adverse Effect Profile

Hyperglycemia / Diabetes	<5% incidence; most Grade 1–2; monitor fasting glucose at baseline, 4 weeks, and 12 weeks; avoid in uncontrolled diabetes
Hepatic enzyme elevation (AST/ALT)	At doses ≥50 mg; fully reversible on discontinuation; check LFTs at baseline and periodically during treatment
Nausea	Low frequency; Grade 1–2; usually self-limiting; timing adjustment (take before larger meal) may help
Headache	Low frequency; observed at ≥50 mg dose; typically Grade 1–2
Dizziness	Rare; Grade 1; generally transient
Fatigue / Asthenia	Common — similar incidence to placebo in cancer patient population; often disease-related rather than drug-related
QTc prolongation	No clinically significant effect observed across trials — lower cardiac risk than many appetite stimulants
Thromboembolic events	Not reported — significant advantage over megestrol acetate, which carries thromboembolic risk
GH tachyphylaxis	Expected with repeated dosing; not an adverse event but a pharmacological adaptation; IGF-1 remains elevated and anabolic benefit is maintained

Patient Selection: Ideal Candidates

Cancer type	NSCLC, gastric, pancreatic, colorectal cancer — approved indications. Other solid tumors: investigational but mechanistically plausible.
Cachexia criterion	≥5% involuntary weight loss within 6 months, OR BMI <20 kg/m² with cancer diagnosis

Cachexia stage	Pre-cachexia or cachexia (NOT refractory) — earlier intervention yields better outcomes
ECOG Performance Status	PS 0–2 preferred; PS 2 tolerable with closer monitoring; PS ≥3 associated with limited benefit and higher ADR rates
Age	<75 years shows superior response; ≥75 requires careful benefit-risk assessment
NLR at baseline	NLR <4.4 predicts better response and improved 1-year overall survival. NLR ≥5 associated with attenuated response.
Appetite status	Active appetite loss / anorexia present — a primary target of therapy
Glucose status	Controlled or absent diabetes — uncontrolled diabetes is a contraindication

Monitoring Framework

Assessment	Baseline	4 Weeks	12 Weeks	Action / Target
Body weight	Yes (weekly)	Yes (weekly)	Yes	Target: ≥5% weight gain (CCR criterion)
Blood glucose / HbA1c	Yes	Yes	Yes	Watch for hyperglycemia; adjust if pre-diabetic
IGF-1 / IGFBP-3	Yes	Optional	Yes	Confirm anabolic axis activation; within normal range
AST / ALT	Yes	Yes	Yes	Discontinue if severe; elevations are reversible
Appetite score (FAACT)	Yes	Yes	Yes	CCR criterion: improved appetite required alongside weight gain
NLR (CBC differential)	Yes	Yes	Optional	NLR <4.4 = favorable; ≥5 = reassess benefit-risk
Handgrip strength	Yes	Optional	Yes	Track functional trajectory; key endpoint for exercise intervention
ECOG PS	Yes	Yes	Yes	Higher PS = more ADRs; lower PS = better response

8-Step Clinical Decision Framework

1. Identify cachexia: ≥5% involuntary weight loss in 6 months OR BMI <20 in a cancer patient with active anorexia
2. Assess stage: Confirm pre-cachexia or cachexia (not refractory). Earlier is always better — do not wait.
3. Check NLR: Baseline NLR <4.4 predicts better treatment response and improved 1-year OS. NLR ≥5 should prompt reassessment.
4. Evaluate performance status: ECOG 0–2 is the target range. Higher ADR burden in PS 2; limited benefit in PS ≥3.
5. Screen contraindications: Uncontrolled diabetes, severe hepatic impairment, hypersensitivity, GH-sensitive tumor histologies, pregnancy.
6. Initiate multimodal plan: Anamorelin 100 mg daily before meals + high-protein nutrition (1.2–1.5 g/kg/day) + supervised resistance exercise + omega-3 fatty acid support + nutritional counseling. Document informed consent (investigational outside Japan).
7. Assess response at 8–12 weeks using CCR criteria: ≥5% body weight gain + improved appetite. Continue if responding; discontinue if no benefit.

8. Monitor ongoing: Weekly weight, periodic glucose, LFTs, IGF-1, NLR follow-up at 4 weeks, appetite scoring. Adjust or discontinue based on response trajectory.

Multimodal Cachexia Management — The Full Framework

Anamorelin alone is insufficient. Evidence-based multimodal intervention:

- Pharmacological: Anamorelin 100 mg daily + consider omega-3 fatty acids (EPA/DHA — pro-resolving mediators; activate lipoxins, maresins; support resolution of inflammation) + NSAIDs where appropriate and tolerated
- Nutritional: High-protein diet targeting 1.2–1.5 g/kg/day (ideally timed post-anamorelin dose to leverage appetite stimulation); oral nutritional supplements; registered dietitian consultation
- Exercise: Supervised resistance training is essential — without it, LBM gains from anamorelin are unlikely to translate into functional strength improvement. Moderate aerobic exercise supports metabolic benefits. Begin at whatever intensity the patient can tolerate; progress as cachexia responds.
- Psychosocial: Counseling for appetite-related distress, fear of eating, and body image concerns; patient and family education that cachexia is a syndrome, not a personal failure
- Anti-tumor therapy: Effective cancer treatment remains the most powerful intervention against cachexia — anamorelin is supportive, not primary. Tumor control is the root treatment.
- Timing: Initiate the full multimodal plan at pre-cachexia or early cachexia. Do not wait for refractory disease.

SECTION 7 · A FINAL NOTE

> ***Anamorelin represents something genuinely new in oncology supportive care — a drug that increases lean body mass in actively cachectic cancer patients through a mechanistically coherent, orally bioavailable pathway that no prior approved agent has been able to use.***

That achievement should not be minimized by the handgrip strength data. The inflammatory mediators that cancer deploys against skeletal muscle — TNF-α, IL-6, the downstream NF-κB-driven proteolytic cascade — do not simply retreat because lean mass is accumulating. They impair the contractile machinery of muscle at the cellular level. Anamorelin builds the tissue. The trial designs did not give that tissue a means to become functional. That is a gap in study design, not a pharmacological failure.

The clinical implication is clear: prescribing anamorelin without a concurrent structured resistance exercise program is leaving the most important outcome on the table. The drug creates the anabolic substrate. Exercise converts it into strength, function, and quality of life. These two interventions are mechanistically complementary, and their separation in current trial design is the most significant limitation of the existing evidence base.

The NLR is an underutilized tool. A simple CBC differential — available in any clinical setting, at no additional cost — gives the prescribing clinician meaningful information about tumor inflammatory environment, expected treatment response, and 1-year survival trajectory before a single dose is dispensed. Using it routinely changes the clinical conversation from 'should we try this?' to 'here is what the biology is telling us about this patient's likely response.'

Japan's approval reflects a pragmatic oncological reality: in a patient losing muscle mass and appetite to cancer, a drug that demonstrably reverses both — without accelerating tumor progression, without causing the thromboembolism of megestrol, without the immunosuppression of corticosteroids — represents genuine clinical value. The EMA's refusal reflects a regulatory framework that weighted functional endpoints over meaningful clinical outcomes. Both positions are internally coherent. The practicing clinician must navigate between them with the patient in front of them.

> *Anamorelin is a first-generation solution to a problem that has had no pharmacological solution until now. Its current evidence base is robust enough to use — carefully, in appropriate patients, within a multimodal framework. The next generation of evidence, if it includes structured exercise as a co-intervention, may transform what was a regulatory debate into a clinical consensus.*

Use it early. Pair it with resistance training. Monitor the NLR. Provide the protein. This is what evidence-based supportive oncology care looks like with the tools currently available.

References

1. Temel JS et al. Anamorelin in patients with NSCLC and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17(4):519–531. [Clinical Trial]
2. Pietra C et al. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist: preclinical profile. J Cachexia Sarcopenia Muscle. 2014;5(4):329–337. [Animal Study]
3. Currow D et al. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced NSCLC. Ann Oncol. 2017;28(8):1949–1956. [Clinical Trial]
4. Wakabayashi H et al. Regulatory approval of anamorelin for cachexia in Japan: facts and numbers. J Cachexia Sarcopenia Muscle. 2021;12(1):14–16. [Review]
5. Katakami N et al. Anamorelin (ONO-7643) in Japanese patients with NSCLC and cachexia (ONO-7643-04). Cancer. 2018;124(3):606–616. [Clinical Trial]
6. Hamauchi S et al. Anamorelin (ONO-7643) in advanced GI cancer with cachexia. Cancer. 2019;125(23):4294–4302. [Clinical Trial]
7. Naito T et al. Anamorelin (ONO-7643) in cancer cachexia and low BMI. Cancer. 2022;128(10):2025–2035. [Clinical Trial]
8. Zhang H, Garcia JM. Anamorelin HCl for cancer-anorexia-cachexia in NSCLC. Expert Opin Pharmacother. 2015;16(8):1245–1253. [Review]
9. Garcia JM et al. Anamorelin for cancer cachexia: integrated analysis of two phase 2 trials. Lancet Oncol. 2015;16(1):108–116. [Clinical Trial]
10. Leese PT et al. Effects of age and gender on PK/PD and safety of anamorelin. Clin Pharmacol Drug Dev. 2015;4(2):112–120. [Clinical Trial]
11. Prommer E. Oncology Update: Anamorelin. Palliat Care. 2017;10:1178224217726336. [Review]
12. Takayama K et al. Efficacy and safety of anamorelin: post-hoc subgroup analyses. Cancer Med. 2023;12(3):2918–2928. [Clinical Trial]
13. Fujii H et al. Anamorelin in cancer cachexia management: clinical efficacy, challenges, future directions. Anticancer Res. 2025;45(3):965–976. [Review]